Topline data were announced from a phase 3 trial evaluating gefurulimab in adults with anti-acetylcholine receptor antibody-positive generalised myasthenia gravis.

DEAR DR. ROACH: My husband woke up with double vision about three weeks ago. It appears that his left eye is turned inward ...

An optometrist has prescribed prism glasses, which help a little. He’s been wearing an eye patch to drive short distances.

My husband woke up with double vision about three weeks ago. It appears that his left eye is turned inward and does not move with his right eye. He’s had a prescription for prednisone that did not ...

Dear Dr. Roach: My husband woke up with double vision about three weeks ago. It appears that his left eye is turned inward and does not move with his right eye. He's had a prescription for prednisone ...

A Hawaiian woman, 37, was diagnosed with a rare instance of three overlapping neurological conditions caused by the body's ...

Explore the growing U.S. Zilbrysq (Zilucoplan) market, projected to expand at a CAGR of 21.64% post-FDA approval for anti-AChR antibody-positive generalized myasthenia gravis (gMG). The subcutaneous ...

The company didn’t share specific data for the molecule, gefurulimab, but said it hit all endpoints in the Phase III PREVAIL ...

Results from the Phase III PREVAIL trial (NCT05556096) of gefurulimab demonstrated a statistically significant and clinically ...

AstraZeneca (LSE:AZN) announced promising trial results for gefurulimab, a potential new treatment for generalized myasthenia ...

Detailed price information for Astrazeneca Plc Ord (AZNCF) from The Globe and Mail including charting and trades.

Astrazeneca plc seems on the way to expanding its presence in myasthenia gravis (MG) with positive “high-level” results from ...